Discontinuing imatinib in chronic myeloid leukemia: don't try this at home

Leuk Lymphoma. 2009 Jun;50(6):868-70. doi: 10.1080/10428190902934951.

Authors

Ryan Mattison¹, Richard A Larson

Affiliation

¹ Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL 60637, USA.

PMID: 19455466
DOI: 10.1080/10428190902934951

No abstract available

Publication types

Comment
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use
Benzamides
Drug Administration Schedule
Follow-Up Studies
Fusion Proteins, bcr-abl / genetics
Gene Expression Regulation, Leukemic
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Piperazines / administration & dosage
Piperazines / therapeutic use*
Pyrimidines / administration & dosage
Pyrimidines / therapeutic use*
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Fusion Proteins, bcr-abl